Medpace Holdings Inc. (MEDP)
MEDP Investors Can Participate In The Medpace Holdings, Inc. Securities Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Medpace Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - MEDP
NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace") (NASDAQ:MEDP) concerning possible violations of federal securities laws. On July 22, 2024, after market hours, MedPace announced mixed financial results for the second quarter of 2024 and then slashed its revenue guidance for the third quarter and remainder of the year.
Medpace Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - MEDP
NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace") (NASDAQ:MEDP) concerning possible violations of federal securities laws. On July 22, 2024, after market hours, MedPace announced mixed financial results for the second quarter of 2024 and then slashed its revenue guidance for the third quarter and remainder of the year.
Medpace Being Investigated on Behalf of Medpace Holdings, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace") (NASDAQ:MEDP) concerning possible violations of federal securities laws. On July 22, 2024, after market hours, MedPace announced mixed financial results for the second quarter of 2024 and then slashed its revenue guidance for the third quarter and remainder of the year.
ATTENTION MEDP SHAREHOLDERS: Investors who lost money on Medpace Holdings, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace") (NASDAQ:MEDP) concerning possible violations of federal securities laws. On July 22, 2024, after market hours, MedPace announced mixed financial results for the second quarter of 2024 and then slashed its revenue guidance for the third quarter and remainder of the year.
3 Reasons Growth Investors Will Love Medpace (MEDP)
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
MEDP ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Medpace Holdings, Inc. investment
NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace") (NASDAQ:MEDP) concerning possible violations of federal securities laws. On July 22, 2024, after market hours, MedPace announced mixed financial results for the second quarter of 2024 and then slashed its revenue guidance for the third quarter and remainder of the year.
Medpace (MEDP) Tops Q2 Earnings Estimates
Medpace (MEDP) came out with quarterly earnings of $2.75 per share, beating the Zacks Consensus Estimate of $2.52 per share. This compares to earnings of $1.93 per share a year ago.
Backlog Conversion Likely to Aid Medpace's (MEDP) Q2 Earnings
Continued strength in backlog conversion rate is likely to have boosted Medpace's (MEDP) top line in the second quarter.
Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Medpace (MEDP) Beats Stock Market Upswing: What Investors Need to Know
The latest trading day saw Medpace (MEDP) settling at $443, representing a +1.84% change from its previous close.
Medpace (MEDP) Upgraded to Strong Buy: Here's Why
Medpace (MEDP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
